Cargando…
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
INTRODUCTION: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported to have a lower risk of pneumonitis than program...
Autores principales: | Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Iwasawa, Shunichiro, Sato, Yuki, Harada, Toshiyuki, Kubota, Kaoru, Tokito, Takaaki, Okamoto, Isamu, Furuya, Naoki, Yokoyama, Toshihide, Hosokawa, Shinobu, Iwasawa, Tae, Yamanaka, Takeharu, Okamoto, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Association for the Study of Lung Cancer. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446731/ https://www.ncbi.nlm.nih.gov/pubmed/32858235 http://dx.doi.org/10.1016/j.jtho.2020.08.018 |
Ejemplares similares
-
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study
por: Ikeda, Satoshi, et al.
Publicado: (2022) -
A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020) -
Rationale and protocol design for the TORG1835/NEXT-SHIP study: a
phase II study of carboplatin, etoposide and nintedanib for unresectable
limited/extensive disease small cell lung cancer with idiopathic pulmonary
fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2020) -
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021) -
Impact of antigen avoidance test for fibrotic hypersensitivity pneumonitis in stable phase
por: Okuda, Ryo, et al.
Publicado: (2022)